Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21941854 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL21743267 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL13145355 | 0.98 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL21743274 | 0.96 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL18747350 | 0.96 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL23641970 | 0.96 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL3970208 | 0.92 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL3966966 | 0.92 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL4446649 | 0.92 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AMEN1ATMMAPT | |
| SCHEMBL23641998 | 0.85 | KMT2A (0.52) | SMN1; SMN2KMT2AMEN1ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | SMN1; SMN2 2231/4885KMT2A 35/4885MEN1 1229/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | SMN1; SMN2 3954/4885KMT2A 2557/4885MEN1 2796/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | SMN1; SMN2 2231/4885KMT2A 35/4885MEN1 1229/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | SMN1; SMN2 2231/4885KMT2A 35/4885MEN1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.